Overview
- GenMolVS is built on NVIDIA BioNeMo and the NeMo Agent Toolkit to enable high‑fidelity molecular simulation and virtual screening.
- Persistent will deploy the solution on NVIDIA accelerated compute with AI Enterprise and NIM microservices to support production-grade workloads.
- Agentic workflows automate virtual screening, candidate prioritization and experimental planning to guide wet‑lab work and reduce early‑stage risk.
- Planned enhancements include integrating NVIDIA Nemotron open models to extend capabilities for computational drug discovery.
- Persistent also plans to grow its AI and LLM engineering bench using NVIDIA infrastructure, training and certification, as shares traded 2.48% lower intraday with a near‑6% five‑session decline reported.